Incannex Healthcare Inc. (IXHL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$74.5M
Cash & Equivalents
$16.2M
Quarterly Burn Rate
14 mo
Est. Cash Runway
$41M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase3 Readout | — |
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06146101 | RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA | PHASE3 | Active Not Recruiting | 560 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-06-25 | 8-K | Incannex Healthcare Inc. (IXHL) (CIK 0001873875) - PRESS RELEASE DATED AS OF JUNE 25, 2026 | EDGAR |